Search clinical trials for: camrelizumab；Rivoceranib

Total 440 results

China Medical University, China

Recruiting

PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma

Gastric Cancer | AFP

China
Jun Guo

Not yet recruiting

Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma

Melanoma
Tianjin Medical University Cancer Institute and...

Recruiting

Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma

Esophagus Cancer

China
Wuhan Union Hospital, China

Recruiting

Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma

Soft Tissue Sarcoma | Neoplasms, Connective and Soft Tissue | Sarcoma Metastatic | Sarcoma,Soft Tissue

China
Shanghai Jiao Tong University School of Medicine

Not yet recruiting

Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma

Osteosarcoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

Esophageal Carcinoma

China
Zhongshan Hospital Xiamen University

Unknown

Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer

Hepatic Metastasis of Colorectal Cancer

China
Peking University People's Hospital
Chinese Sarcoma Study Group

Recruiting

Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma (MAPAC)

Osteosarcoma | Chemotherapy Effect | Survival | Toxicity, Drug

China
Sun Yat-sen University
Second Affiliated Hospital of Guangzhou Medical University

Completed

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Liver Diseases | Hepatocellular Carcinoma | Anti-PD1 Antibody

China
Jiangsu HengRui Medicine Co., Ltd.

Enrolling by invitation

A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients

Advanced Solid Tumors

China
Rui-hua Xu, MD, PhD

Not yet recruiting

A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD

Advanced Pancreatic Cancer

China
Hospital of Stomatology, Wuhan University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma (NEOPCOSCC)

Oral Squamous Cell Carcinoma

China
Shengjing Hospital

Recruiting

Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer

HER2-positive Gastric Cancer

China
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma (IMplus)

Head and Neck Squamous Cell Carcinoma

China
Ruijin Hospital

Recruiting

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Peripheral T Cell Lymphoma

China
Fudan University

Not yet recruiting

Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Gastric Neoplasms | Gastroesophageal Junction Adenocarcinoma

China
Shanghai Jiao Tong University School of Medicine

Recruiting

Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients

Oral Squamous Cell Carcinoma | Anti-PD-1 | Neoadjvant Therapy | Anti-VEGFR

China
Hunan Cancer Hospital
Suzhou Sheng Diya Biomedical Co., Ltd.

Active, not recruiting

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Adenocarcinoma of the Lung

China
Chinese PLA General Hospital

Unknown

Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer

Advanced Gastric Cancer

China
Fujian Cancer Hospital

Unknown

PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer

Advanced Gastric Adenocarcinoma

China
Wuhan University

Recruiting

SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy (SABRE)

Non-Small Cell Lung Cancer

China
RenJi Hospital

Recruiting

A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV

China
National Institute of Allergy and Infectious Diseases...

Completed

A Study of Didanosine Use Alone or in Combination With Zidovudine in Infants Exposed to or Infected With HIV

HIV Infections

United States, Puerto Rico
National Cancer Institute (NCI)

Completed

A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection

HIV Infections

United States
Fujian Medical University

Active, not recruiting

Camrelizumab Combined With Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

Advanced Gastric Cancer

China
Zhou Chengzhi
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC

Extensive Stage Small Cell Lung Cancer

China
The First Affiliated Hospital of Xiamen University

Unknown

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

Locally Advanced or Metastatic Gastric Adenocarcinoma

China
Huazhong University of Science and Technology

Not yet recruiting

Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas

Advanced or Metastatic EP-NEC

China
Zhou Fuxiang
Hubei Cancer Hospital; Henan Provincial People's Hospital; Huangshi Central Hospital...

Recruiting

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma

China
Qilu Hospital of Shandong University
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer
Beijing Friendship Hospital

Unknown

Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer

Gastric Cancer

China
China Medical University, China

Not yet recruiting

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

PD-1 Antibody | Gastrointestinal Tumours | DC-Cell | NK-Cell
Peking Union Medical College Hospital

Recruiting

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma | PD-1 Inhibitor | Regorafenib

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC

Small-cell Lung Cancer
Tongji Hospital
Zhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaborators

Not yet recruiting

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Cervical Cancer | Locally Advanced Cervical Cancer | Concurrent Chemoradiotherapy | Neoadjuvant Chemoimmunotherapy

China
MingSight Pharmaceuticals, Inc

Recruiting

A Study Of The Selective PKC-β Inhibitor MS- 553

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Aggressive Lymphoma

United States
Eye & ENT Hospital of Fudan University

Active, not recruiting

Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

Chemotherapy | Immunotherapy | Hypopharyngeal Carcinoma

China
Fuzhou General Hospital

Unknown

Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.

Small Cell Lung Cancer | Lung Neoplasm | PD-1 Inhibitors

China
Guangzhou Institute of Respiratory Disease
Jiangsu HengRui Medicine Co., Ltd.; BGI-Shenzhen

Completed

Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma | Immunotherapy

China
Cancer Institute and Hospital, Chinese Academy...
The First Affiliated Hospital with Nanjing Medical University; Fujian Cancer... and other collaborators

Recruiting

PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer

Esophageal Neoplasms

China
CrystalGenomics, Inc.

Recruiting

Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Non Squamous Non Small Cell Lung Cancer

Korea, Republic of
West China Hospital

Recruiting

Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

BRAF V600E-mutated /MSS Metastatic Colorectal Cancer | Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody

China
Nanfang Hospital of Southern Medical University

Recruiting

A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer

Gastric Cancer

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Terminated

A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
Tang-Du Hospital

Active, not recruiting

Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC

Non-small-cell Lung Cancer (NSCLC)

China
The First Affiliated Hospital with Nanjing Medical...

Enrolling by invitation

Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Fujian Medical University Union Hospital

Not yet recruiting

Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma

Chemotherapy | Radiation Therapy

China
Fujian Medical University

Not yet recruiting

Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

Locally Advanced Gastric Cancer

China
Sun Yat-sen University

Recruiting

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

Nasopharyngeal Carcinoma

China

3

Subscribe